amonafide amonafide amonafide (originally as1413) (inn, trade names quinamed and xanafide) was a drug that was being studied in the treatment of cancer. it belongs to a novel family of chemotherapeutic drugs called naphthalimides and is a potential topoisomerase inhibitor and dna intercalator. amonafideclinical datatrade namesxanafide, quinamedatc codenoneidentifiers iupac name 5-amino-2--1h-benzoisoquinoline-1,3(2h)-dione cas number69408-81-7pubchem cid50515chemspider45804 yunii1q8d39n37lkeggd10090 ychemblchembl428676 ycomptox dashboard (epa)dtxsid30219562 chemical and physical dataformulac16h17n3o3molar mass299.330 g·mol−13d model (jsmol)interactive image smiles o=c2c1c3c(ccc1)cc(cc3c(=o)n2ccn(c)c)n inchi inchi=1s/c16h17n3o2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9h,6-7,17h2,1-2h3 ykey:upaliksflsvkis-uhfffaoysa-n y (verify) it was being developed as an anti-cancer therapy by antisoma. as of 2008, it is in phase iii clinical trials. e.g. in march 2010 it is phase iii trial against secondary acute myeloid leukaemia (aml). in june 2010, it gained an fda fast track status for the treatment of secondary acute myeloid leukaemia.